Comment Bien Trader les Valeurs Biotechnologiques Françaises - Séminaire Coach Boursier 2017

"Investir dans les Biotechs est risqué et nécessite un suivi régulier des cours et l’accès aux sources d’informations de qualité, en raison de changements constants dans le domaine, mais aussi longtemps que vous investissez dans des sociétés capables de maintenir une solide assise de revenu et de trésorerie dépassant les dépenses en R&D, d’avoir une ligne établie de produits approuvés par la FDA et qui continuent d’enrichir le pipeline de produits, en obtenant des approbations pour des essais cliniques de Phase III à venir, la solidité peut être maintenue et se poursuivrait naturellement sur le long terme." (TheStreet's Biotech Bible: A Compendium of Biotech Companies for Today's Investor, de TheStreet Staff (Auteur), Jim Cramer (Introduction))

"Investing in Biotechs is risky & requires regular maintenance/monitoring, due to constant changes in the field, though as long as you invest in companies capable of upholding a strong base of generating revenue & cash flow outweighing their R&D expenditures, have an established line of FDA approved products and continue to steadily build/grow their product pipeline, by establishing successful upcoming Phase III approvals, solidity may be maintained & would naturally follow for the long term." (TheStreet's Biotech Bible: A Compendium of Biotech Companies for Today's Investor, de TheStreet Staff (Auteur), Jim Cramer (Introduction))

"investing in biotech is an art that requires fluency in both business and science, as well as sophisticated translational skills to connect the two worlds." EcoR1 Capital

Build Biotech Wealth on Solid Platforms: Grant Zeng (Source: Peter Byrne and Tracy Salcedo-Chourré of The Life Sciences Report  (4/17/14))

  • "First, I look at the technology. It's critical that the company has a platform technology, because that enables the creation of products and processes that support present or future development. If a biotech owns a platform technology, it is much easier to build a robust pipeline in a cost-effective way, and save time.
  • Second, I look at the company's pipeline. Generally speaking, a diversified, robust pipeline, with multiple product candidates in various stages of development, is more valuable than a single-product pipeline. Of course, I also look at each individual drug candidate, its targeted population and its market potential.
  • Third, I look at the company's balance sheet. Cash burn is always a concern for a small-cap biotech. A strong balance sheet allows a company to focus on its long-term growth without considering short-term cash strains."

SÉMINAIRE COACH BOURSIER PARIS 2017 - COACH BOURSIER SEMINAR PARIS 2017